Revance Therapeutics, Inc. (RVNC) Q3 2023 Earnings Call Transcript


Revance Therapeutics, Inc. (NASDAQ:RVNC) Q3 2023 Earnings Conference Call November 8, 2023 4:30 PM ET

Company Participants

Jessica Serra – Head, IR, Communications & ESG

Mark Foley – CEO

Dustin Sjuts – President

Toby Schilke – CFO

Conference Call Participants

Seamus Fernandez – Guggenheim Partners

Mikaela Franceschina – Barclays

David Amsellem – Piper Sandler

Stacy KU – TD Cowen

Annabel Samimy – Stifel

Uy Ear – Mizuho

Serge Belanger – Needham and Company

Douglas Tsao – H.C. Wainwright

Terence Flynn – Morgan Stanley

Navann Ty – BNP Paribas

Operator

Welcome to the Revance Therapeutics Third Quarter 2023 Financial Results and Corporate Update Conference Call. At this time, all participants are in a listen-only mode. Following management’s prepared remarks, we will hold a question and answer session. [Operator Instructions]. As a reminder, this call is being recorded today, Wednesday, November 8, 2023.

I would now like to turn the conference call over to Jessica Serra, Head of Investor Relations, Communications and ESG for Revance. Please go ahead.

Jessica Serra

Thank you, operator. Joining us on the call today from Revance are Chief Executive Officer, Mark Foley, President, Dustin Sjuts, and Chief Financial Officer, Toby Schilke. During this conference call, management will make forward-looking statements, including statements related to guidance, positive adjusted EBITDA, adjusted gross margins, operating leverage, blockbuster potential.

The financial impact of OPUL exit, the impact of our pricing strategy and adoption, our competitive market position, our potential value creation, additional therapeutics approvals, plans related to the timing of launch and payer coverage of DAXXIFY for cervical dystonia, international expansion, relationships with providers, our commercial success, injector, consumer and patient preferences and behavior, the efficacy duration and safety of DAXXIFY, the benefits of our products and strategy, our strategic partnership shifts and strategy, timeline, goals and planned operations.

Our actual



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *